143 related articles for article (PubMed ID: 10770430)
1. Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma.
Bayer-Garner IB; Dilday B; Sanderson RD; Smoller BR
Am J Dermatopathol; 2000 Apr; 22(2):119-22. PubMed ID: 10770430
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1 expression is diminished in acantholytic cutaneous squamous cell carcinoma.
Bayer-Garner IB; Sanderson RD; Smoller BR
J Cutan Pathol; 1999 Sep; 26(8):386-90. PubMed ID: 10551410
[TBL] [Abstract][Full Text] [Related]
3. Dermatofibroma: upregulation of syndecan-1 expression in mesenchymal tissue.
Sellheyer K; Smoller BR
Am J Dermatopathol; 2003 Oct; 25(5):392-8. PubMed ID: 14501288
[TBL] [Abstract][Full Text] [Related]
4. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma.
Mukunyadzi P; Sanderson RD; Fan CY; Smoller BR
Mod Pathol; 2002 Jan; 15(1):45-9. PubMed ID: 11796840
[TBL] [Abstract][Full Text] [Related]
5. Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation.
Ito Y; Yoshida H; Nakano K; Takamura Y; Miya A; Kobayashi K; Yokozawa T; Matsuzuka F; Matsuura N; Kuma K; Miyauchi A
Histopathology; 2003 Aug; 43(2):157-64. PubMed ID: 12877731
[TBL] [Abstract][Full Text] [Related]
6. The expression of syndecan-1 is preferentially reduced compared with that of E-cadherin in acantholytic squamous cell carcinoma.
Bayer-Garner IB; Smoller BR
J Cutan Pathol; 2001 Feb; 28(2):83-9. PubMed ID: 11168756
[TBL] [Abstract][Full Text] [Related]
7. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
Mikami S; Ohashi K; Usui Y; Nemoto T; Katsube K; Yanagishita M; Nakajima M; Nakamura K; Koike M
Jpn J Cancer Res; 2001 Oct; 92(10):1062-73. PubMed ID: 11676857
[TBL] [Abstract][Full Text] [Related]
8. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-1 is strongly expressed in the anagen hair follicle outer root sheath and in the dermal papilla but expression diminishes with involution of the hair follicle.
Bayer-Garner IB; Sanderson RD; Smoller BR
Am J Dermatopathol; 2002 Dec; 24(6):484-9. PubMed ID: 12454600
[TBL] [Abstract][Full Text] [Related]
10. Immunolabeling pattern of syndecan-1 expression may distinguish pagetoid Bowen's disease, extramammary Paget's disease, and pagetoid malignant melanoma in situ.
Bayer-Garner IB; Reed JA
J Cutan Pathol; 2004 Feb; 31(2):169-73. PubMed ID: 14690462
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical localization of syndecan in mouse skin tumors induced by UV irradiation. Loss of expression associated with malignant transformation.
Inki P; Stenbäck F; Talve L; Jalkanen M
Am J Pathol; 1991 Dec; 139(6):1333-40. PubMed ID: 1750507
[TBL] [Abstract][Full Text] [Related]
12. Syndecan-1 expression--a novel prognostic marker in pancreatic cancer.
Juuti A; Nordling S; Lundin J; Louhimo J; Haglund C
Oncology; 2005; 68(2-3):97-106. PubMed ID: 15886501
[TBL] [Abstract][Full Text] [Related]
13. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
14. The role of syndecan-1 in malignancies.
Inki P; Jalkanen M
Ann Med; 1996 Feb; 28(1):63-7. PubMed ID: 8932508
[TBL] [Abstract][Full Text] [Related]
15. Syndecan-1 in B lymphoid malignancies.
Sanderson RD; Børset M
Ann Hematol; 2002 Mar; 81(3):125-35. PubMed ID: 11904737
[TBL] [Abstract][Full Text] [Related]
16. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
[TBL] [Abstract][Full Text] [Related]
17. Expression of proteoglycan core proteins in human bone marrow stroma.
Schofield KP; Gallagher JT; David G
Biochem J; 1999 Nov; 343 Pt 3(Pt 3):663-8. PubMed ID: 10527946
[TBL] [Abstract][Full Text] [Related]
18. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.
Mukunyadzi P; Liu K; Hanna EY; Suen JY; Fan CY
Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224
[TBL] [Abstract][Full Text] [Related]
19. Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin.
Gallo R; Kim C; Kokenyesi R; Adzick NS; Bernfield M
J Invest Dermatol; 1996 Nov; 107(5):676-83. PubMed ID: 8875948
[TBL] [Abstract][Full Text] [Related]
20. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells.
Maeda T; Alexander CM; Friedl A
Cancer Res; 2004 Jan; 64(2):612-21. PubMed ID: 14744776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
